Vizimpro(Dacomitinib)
PFE
Medicare prescription drug cost, prescriptions and prescribers, 2024 · made by Pfizer Inc.
$2.6M
Medicare cost, 2024
$2.6M
Medicare cost, 2024
Medicare drug plans spent $2.6 million on Vizimpro (dacomitinib) in 2024, for 163 prescriptions and refills filled by 37 patients. At about $15,894 per prescription it is a high-cost drug. New York accounts for the most spending ($595,099, 23% of the total). It is made by Pfizer Inc. (PFE).
Medicare cost, 2024
$2.6M
-6.6% from 2023
Prescriptions
163
$15,894.44 per claim
Patients
37
37 prescribers
Total spending, 2024
$2.6M
$70,021.44 per patient
Questions and answers
How much does Medicare spend on Vizimpro?
Medicare prescription drug plans paid $2.6M for Vizimpro in 2024, for 163 prescriptions and refills to 37 patients (down 6.6% from 2023). The average cost per claim was $15,894.44.
Which state spends the most on Vizimpro?
New York had the highest Medicare cost for Vizimpro in 2024: $595K for 37 claims, followed by California ($401K).
Who prescribes Vizimpro the most?
Bob T Li, medical oncology in New York, NY, had the highest Medicare cost for Vizimpro in 2024: 17 claims costing $268K.
Who makes Vizimpro?
Vizimpro is made by Pfizer Inc. (PFE), listed in the Medicare spending data as Pfizer US Pharm.
Spending over the years
Medicare spending by year
All plans and makers
Prescriber data: cost by year
Medicare spending on Vizimpro was $2.6M in 2024, after a high of $2.8M in 2023.
By state
Where the prescribers practice, 2024
Medicare cost by state
States with the highest cost
Top prescribers of Vizimpro, 2024
By Medicare drug cost
| Prescriber | Type | Claims | Patients | Cost |
|---|---|---|---|---|
| Bob T Li New York, NY | Medical Oncology | 17 | Under 11 | $268K |
| Jyoti Malhotra New Haven, CT | Hematology-Oncology | 13 | Under 11 | $204K |
| Jorge A Diaz Huntsville, AL | Hematology-Oncology | 12 | Under 11 | $185K |
| Bety C Ciobanu Chicago, IL | Internal Medicine | 11 | Under 11 | $165K |
| Sumeet Bhatia Indianapolis, IN | Medical Oncology | 12 | Under 11 | $132K |
Prescriber data by year
| Year | Prescribers | Claims | Patients | Cost |
|---|---|---|---|---|
| 2022 | 32 | 150 | 30 | $2.4M |
| 2023 | 37 | 174 | 35 | $2.8M |
| 2024 | 37 | 163 | 37 | $2.6M |
Makers, 2024
Spending by manufacturer as listed in the spending data
| Manufacturer | Claims | Spending |
|---|---|---|
| Pfizer US Pharm | 163 | $2.6M |
Codes
- National drug codes (packages)
- 3
- RxNorm concept IDs
- 2058915, 2058922, 2058924, 2058926, 2058930
- Application numbers
- NDA211288
More drugs: Medicare drug spending and the Prescriptions view.
Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.
Through September 2026, 749 side-effect reports named dacomitinib, the active ingredient of Vizimpro (reports from 2012 on). 692 of them (92.4%) were serious, 330 named a death and 215 named a hospital stay. The reactions named most often were death, diarrhoea and rash. 447 reports came in the last 5 years (since 2022).
How to read these numbers
- A report shows that a patient, doctor or drug company suspected a link. It does not prove that the drug caused the effect.
- Counts are not risk rates. They depend on how many people use the drug, how long it has been sold, news and reporting habits, so they do not show which drug is safer.
- The newest months are partial: reports keep arriving late.
Reports, all years
749
41 in 2025 (-25.5% from 2024)
Serious
92.4%
692 reports
Deaths named
330
44.1% of reports
Hospital stays
215
28.7% of reports
Reports by year
Serious reports include those that name a death, a hospital stay, a disability or another serious outcome.
Reports received by year
2026 is the year so far.
Reports naming a death or a hospital stay
One report can name both
Reactions
Reactions named most often
All years. Share = part of all reports in that period. A report can name several reactions.
Patients
As given in the reports; many reports leave sex or age out.
Sex of the patient
All years
Age of the patient
Age when the effect started, all years
Questions and answers
How many side-effect reports name Vizimpro?
749 reports from 2012 through September 2026 named dacomitinib, the active ingredient of Vizimpro. 692 of them (92.4%) were serious, 330 named a death and 215 named a hospital stay.
What are the most reported side effects of Vizimpro?
238 reports named death, the reaction named most often, followed by diarrhoea (121) and rash (115). In the last 5 years the reaction named most often was death (135 reports). A report can name several reactions.
How many side-effect reports named Vizimpro in 2025?
41 reports were received in 2025 (-25.5% from 2024). 2026 so far: 16 reports through September 2026, and more keep arriving late.
Do side-effect reports prove that Vizimpro caused a problem?
No. A report shows that a patient, doctor or drug company suspected a link; it does not prove that Vizimpro caused the effect. Report counts depend on how widely a drug is used, how long it has been sold, news and reporting habits, so they are not risk rates and do not show which drug is safer.
Related pages
- Makers on the stock market:
PFE·PFE drug pipeline - Drug approvals (1 approval on file for dacomitinib) · Clinical trials · Medicare drug spending
Side-effect reports from official public data, counted per active ingredient (dacomitinib) by the year the report was received, so the brand and generic pages of one ingredient show the same reports. A report can name several drugs and several reactions and counts for each. Reaction names are the standard medical terms used in the reports. Reports whose product could not be matched to a drug are not counted. Updated November 2026.